STAAR Surgical Company (NASDAQ:STAA) Receives $26.94 Average PT from Brokerages

Shares of STAAR Surgical Company (NASDAQ:STAA) have been assigned a consensus recommendation of “Hold” from the thirteen ratings firms that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $26.9444.

STAA has been the subject of several analyst reports. Wall Street Zen downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Mizuho upped their price objective on STAAR Surgical from $22.00 to $27.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Canaccord Genuity Group increased their target price on STAAR Surgical from $27.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, May 14th. Piper Sandler lifted their target price on STAAR Surgical from $16.00 to $33.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Finally, Stifel Nicolaus boosted their price target on STAAR Surgical from $18.00 to $31.00 and gave the stock a “hold” rating in a research note on Thursday, May 14th.

STAAR Surgical Stock Performance

Shares of STAAR Surgical stock opened at $23.12 on Tuesday. STAAR Surgical has a 1 year low of $15.59 and a 1 year high of $35.87. The firm’s 50-day moving average is $27.31 and its 200 day moving average is $23.96. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -53.77 and a beta of 1.26. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.12 and a quick ratio of 4.31.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings data on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.05. The business had revenue of $93.52 million during the quarter, compared to analyst estimates of $78.72 million. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. STAAR Surgical’s revenue was up 119.6% compared to the same quarter last year. During the same period last year, the business earned ($1.10) EPS. Sell-side analysts anticipate that STAAR Surgical will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On STAAR Surgical

Large investors have recently bought and sold shares of the business. Tudor Investment Corp ET AL purchased a new position in shares of STAAR Surgical in the 3rd quarter worth $4,113,000. GSA Capital Partners LLP purchased a new stake in STAAR Surgical during the fourth quarter valued at $910,000. UBS Group AG lifted its holdings in STAAR Surgical by 39.2% in the fourth quarter. UBS Group AG now owns 327,852 shares of the medical instruments supplier’s stock valued at $7,570,000 after acquiring an additional 92,321 shares during the period. American Capital Management Inc. lifted its holdings in STAAR Surgical by 18.7% in the first quarter. American Capital Management Inc. now owns 878,035 shares of the medical instruments supplier’s stock valued at $16,419,000 after acquiring an additional 138,499 shares during the period. Finally, Crcm LP purchased a new position in STAAR Surgical in the first quarter worth about $1,870,000. 96.70% of the stock is currently owned by institutional investors.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.